EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Evaluating Efficacy and Safety of Crisaborole in Managing Childhood Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-Analysis

Jianhua You, Huanmei Li, Zhongyun Wang, Yunfei Zhao iD

British Journal of Hospital Medicine · 2025

DOI: 10.12968/hmed.2024.0575 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift British Journal of Hospital Medicine, 2025. Verfasst von Jianhua You und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Zhejiang Institute of Skin Disease Control, Huzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Boron Compounds, Bridged Bicyclo Compounds, Heterocyclic, Dermatologic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Background Atopic dermatitis (AD) is a common chronic inflammatory skin disorder globally. Crisaborole, a nonsteroidal topical phosphodiesterase 4 inhibitor (PDE4i), has been utilized in treating AD. Crisaborole regulates the production of inflammatory cytokines, which are usually overactive among AD patients. Therefore, this study aimed to explore the efficacy and safety of crisaborole in treating AD in patients aged ≤18 years.

Methods

A literature search was performed across PubMed, MEDLINE, Embase, Cochrane, and Google Scholar. The inclusion criteria involved primary studies evaluating the effect of crisaborole in treating dermatitis, articles exploring the use of crisaborole in AD patients below 18 years (>two years), and articles published in English between 2000 and 2022. However, the studies evaluating AD in adult patients, those reporting treatments other than crisaborole, those published before 2000, and articles written in languages other than English were excluded from this analysis. Furthermore, secondary data sources such as case reports, newspaper articles, magazines, and other systematic reviews and meta-analyses were excluded. A meta-analysis was conducted using RevMan 5.4. The risk of bias in the manuscripts was assessed using the Cochrane tool. The I-square test statistic was used to determine heterogeneity, and Egger’s test was used to evaluate publication bias.

Results

Ten studies met the eligibility criteria and were included in the final analysis. Most of the studies exhibited a low risk of bias with no publication bias. Meta-analysis indicated a significant difference in the number of patients attaining Investigator Static Global Assessment (ISGA) success at day 29, with significantly higher patients in the crisaborole group than in the vehicle group (odds ratio (OR) 1.56, 95% CI 1.24 to 1.96; I 2 = 77%; p = 0.0001). Similarly, pruritus improvement was significant between the two cohorts at day 29, indicating significantly higher heterogeneity (OR 1.70, 95% CI 1.10 to 2.63; I 2 = 91%; p = 0.02). Furthermore, the safety profiling of the treatments was insignificant, demonstrating no statistical difference in the treatment-emergent adverse events (TEAEs) between the two groups with high heterogeneity (OR 0.53, 95% CI 0.14 to 1.98; I 2 = 99%; p = 0.35).

Conclusion

Crisaborole demonstrates substantial efficacy in treating mild to moderate AD compared to vehicle therapies, as it reduces the signs and symptoms of the disease. Furthermore, crisaborole is well tolerated and has an acceptable safety profile in treating mild to moderate AD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicBoron CompoundsBridged Bicyclo Compounds, HeterocyclicDermatologic AgentsHumansChildTreatment OutcomeAdolescentSeverity of Illness Index

Stichwörter der Autor:innen

atopic dermatitiscrisaboroledermatologic diseasespediatricsphosphodiesterase 4 inhibitorpruritus

Substanzen

crisaboroleBoron CompoundsBridged Bicyclo Compounds, HeterocyclicDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Zhejiang Institute of Skin Disease Control, Huzhou, Zhejiang, China.
  • Department of Aesthetic Physiotherapy, Zhejiang Institute of Skin Disease Control, Huzhou, Zhejiang, China.
  • Department of Pediatrics, Taizhou Women and Children's Hospital, Taizhou, Zhejiang, China.

ORCID-Profile: Yunfei Zhao

Zitieren

APA

You, J., Li, H., Wang, Z., & Zhao, Y. (2025). Evaluating Efficacy and Safety of Crisaborole in Managing Childhood Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-Analysis. British Journal of Hospital Medicine. https://doi.org/10.12968/hmed.2024.0575

Vancouver

You J, Li H, Wang Z, Zhao Y. Evaluating Efficacy and Safety of Crisaborole in Managing Childhood Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-Analysis. British Journal of Hospital Medicine. 2025. doi:10.12968/hmed.2024.0575

BibTeX
@article{You2025,
  author = {You, Jianhua and Li, Huanmei and Wang, Zhongyun and Zhao, Yunfei},
  title = {Evaluating Efficacy and Safety of Crisaborole in Managing Childhood Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-Analysis},
  journal = {British Journal of Hospital Medicine},
  year = {2025},
  doi = {10.12968/hmed.2024.0575}
}
Kostenlos starten →